» Articles » PMID: 33202693

IL-18 but Not IL-1 Signaling Is Pivotal for the Initiation of Liver Injury in Murine Non-Alcoholic Fatty Liver Disease

Abstract

Non-alcoholic fatty liver disease (NAFLD) is rising in prevalence, and a better pathophysiologic understanding of the transition to its inflammatory phenotype (NASH) is key to the development of effective therapies. To evaluate the contribution of the NLRP3 inflammasome and its downstream effectors IL-1 and IL-18 in this process, we applied the true-to-life "American lifestyle-induced obesity syndrome" (ALiOS) diet mouse model. Development of obesity, fatty liver and liver damage was investigated in mice fed for 24 weeks according to the ALiOS protocol. Lipidomic changes in mouse livers were compared to human NAFLD samples. Receptor knockout mice for IL-1 and IL-18 were used to dissect the impact of downstream signals of inflammasome activity on the development of NAFLD. The ALiOS diet induced obesity and liver steatosis. The lipidomic changes closely mimicked changes in human NAFLD. A pro-inflammatory gene expression pattern in liver tissue and increased serum liver transaminases indicated early liver damage in the absence of histological evidence of NASH. Mechanistically, - but not mice were protected from early liver damage, possibly due to silencing of the pro-inflammatory gene expression pattern. Our study identified NLRP3 activation and IL-18R-dependent signaling as potential modulators of early liver damage in NAFLD, preceding development of histologic NASH.

Citing Articles

Interleukins: Pathogenesis in Non-Alcoholic Fatty Liver Disease.

Rafaqat S, Gluscevic S, Mercantepe F, Rafaqat S, Klisic A Metabolites. 2024; 14(3).

PMID: 38535313 PMC: 10972081. DOI: 10.3390/metabo14030153.


Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the mouse model of sclerosing cholangitis.

Fuchs C, Sroda N, Scharnagl H, Gupta R, Minto W, Stojakovic T JHEP Rep. 2023; 5(11):100874.

PMID: 37841639 PMC: 10568427. DOI: 10.1016/j.jhepr.2023.100874.


Overview of Cellular and Soluble Mediators in Systemic Inflammation Associated with Non-Alcoholic Fatty Liver Disease.

Marques P, Francisco V, Martinez-Arenas L, Carvalho-Gomes A, Domingo E, Piqueras L Int J Mol Sci. 2023; 24(3).

PMID: 36768637 PMC: 9916753. DOI: 10.3390/ijms24032313.


Interleukin-18 in metabolism: From mice physiology to human diseases.

Somm E, Jornayvaz F Front Endocrinol (Lausanne). 2022; 13:971745.

PMID: 36313762 PMC: 9596921. DOI: 10.3389/fendo.2022.971745.


High-fat diet combined with dextran sulfate sodium failed to induce a more serious NASH phenotype than high-fat diet alone.

Zhou Y, Feng Y, Yang L, Zheng P, Hang L, Jiang F Front Pharmacol. 2022; 13:1022172.

PMID: 36238563 PMC: 9551200. DOI: 10.3389/fphar.2022.1022172.


References
1.
Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal W, Strowig T . Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482(7384):179-85. PMC: 3276682. DOI: 10.1038/nature10809. View

2.
Sanyal A . Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019; 16(6):377-386. DOI: 10.1038/s41575-019-0144-8. View

3.
Flisiak-Jackiewicz M, Bobrus-Chociej A, Tarasow E, Wojtkowska M, Bialokoz-Kalinowska I, Lebensztejn D . Predictive Role of Interleukin-18 in Liver Steatosis in Obese Children. Can J Gastroenterol Hepatol. 2018; 2018:3870454. PMC: 5944203. DOI: 10.1155/2018/3870454. View

4.
Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

5.
Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View